PHL Synaptik’s Post

Congratulations to winners of our 2024 OneTRI Awards, recognising people who embody our values of leadership, integrity, knowledge, excellence and collaboration – and our culture of partnership, support, diversity and inclusion. The winners for 2024 are: - OneTRI Unsung Hero, demonstrating excellence in leadership and support of research: TRI Engagement Managers Glenda Colburn, Julia Renaud and Benedette Watson - Discovery Platforms, for implementing novel approaches and technologies to enhance research: Professor Ranjeny Thomas from The University of Queensland #FrazerInstUQ. - Connecting with the Clinic, for leading collaborations between researchers and healthcare partners: Professor Josephine Forbes from Mater Research - Developing and/or Manufacturing Diagnostics and Therapeutics, demonstrating evidence of progression: the Vaxxas team - Clinical Trial and Industry Growth, leading to development, impact and outcomes: AdvanCell - OneTRI Award, for excellence in collaboration, contributing to a welcoming workplace and exemplifying TRI values: Michelle Spraggon. Pictured are the recipients in attendance and award presenters.

See you there, if you want to learn more about the myeloid cell "mess" and how to target it in fibrotic diseases.

Innovation in action

Exciting News: ALTERTOX and DCL solutions Partner Up for NAMs and 3Rs Advancement! We're thrilled to announce a powerful new partnership between @Altertox and @DCL solutions! This collaboration brings together industry leaders with a shared mission: to transform how we tackle New Alternative Methods (#NAMs) and advance the principles of #3Rs (#Replacement, #Reduction, and #Refinement) in science. Through this partnership, we'll be exploring innovative solutions to: · Accelerate the adoption of NAMs: We'll work together to make NAMs more accessible and user-friendly for scientists worldwide. · Drive impactful advancements in the 3Rs: By leveraging our combined expertise, we'll develop new strategies to reduce and refine animal testing while maintaining scientific rigor. · Set a dialogue across all stakeholders: Comprehensive assessment of scientific approaches will foster the acceptance of new models and new mindset.  Stay tuned for more exciting developments as this #partnership unfolds! We're committed to making a positive impact on the future of scientific research. Let us know in the comments below what you're most excited about with this collaboration!   #NAMs #3Rs #Science #Partnership #Altertox #DCLSolutions #Innovation    

Things are moving quickly...

Check out my recent pitch at the MedInvest conference in San Francisco. We are making great progress. We have filled about half of our Series B. We would like to welcome additional investors. #Newronika #Brainmodulation #Parkinsons #Neuromodulation #DBS #adaptiveDBS #aDBS #venturecapital #alphaDBS

We are on the final countdown to #WorldADC London! Addressing the current state of the ADC landscape and asking what we expect to see progressing through the clinic next, is our Account Lead, Jake Morris. Full details of the talk are: 📈 The total number of ADC programs has increased massively over the last few years, what are the emerging trends from this recent influx of activity? 🔬 From Payloads & Linkers to Targets & Bispecifics, which approaches are seeing the most use in each stage of development? 💊 What were the key highlights and updates for ADC development across 2023? Download the full event guide today to get full details of the 4-day agenda, including our Pre-Conference Seminar Day ADC combination in clinical trials presentation. 👇 https://lnkd.in/ePtRPBYq Catch our ADC team, Jia, Jake, Raj, and Eleni, in the exhibition hall at booth #34 and grab some goodies too! #WorldADC #WADC #drugdevelopment #ADClandscape #payloads #targets #bispecifics #ADCcombination #clinicaltrials

We are excited to share with you our ambitions for the next 4 years. Building on the achievements of the past strategic plan, and the decade since ECRIN has achieved its ERIC status, the new strategic plan is marks a consolidation phase for ECRIN. To meet our objectives we have built the strategic plan around five overarching goals to drive ECRIN’s activity for 2024-2027: 1) Ensure scientific excellence and public health relevance 2) Cultivate a thriving and empowered ECRIN community 3) Forging the path for future ECRIN activities 4) Consolidate and promote our visibility and awareness 5) Sustain engagement with the research infrastructure ecosystem Delve into our strategic plan today: https://lnkd.in/eAmEEcT3 CZECRIN, Infrastructure F-CRIN, GreCRIN, HNHRA, HRB National Clinical Trials Office (NCTO), ItaCRIN, KKSN, NorCRIN, PCTN, PtCRIN Portuguese Clinical Research Infrastructure Network, Spanish Clinical Research Network (SCReN), SLOVACRIN, Swiss Clinical Trial Organisation, ERIC Forum

🌟 Exciting News! 🌟 Business Oregon has awarded over $1.5 million in SBIR/STTR Matching Grants to 20 innovative small businesses across the state! These matching funds support companies advancing groundbreaking research and development, bringing cutting-edge technologies closer to market. We’re thrilled to celebrate this milestone with OBI client companies Madorra Inc., Vivifi Medical and OBI alumni Trace Biosciences among the awardees! Congrats to all recipients for driving progress and fueling small business growth! #OBI4You #SBIR #STTR https://lnkd.in/gH9kmg5D

VCTC are at OCT UK 🚀 You can find Dan Henley, Helen Shaw (nee Kirkby), and Hugh McEnery at Booth 18 👋 Stop by to learn how our patient-centric research site can help deliver your trials faster and more cost-effectively💡 #OCTUK #VCTC #TheVirtualClinicalTrialCentre #ClinicalTrials #TheVCTC #DecentrialisedTrials #PatientCentricity #EmpoweringPatients #FutureofHealth